SIK1 Inhibitors
1 drugsAbout SIK1
Salt-inducible kinase 1 (SIK1) is a serine/threonine kinase involved in cellular metabolism, stress response, and immune function. While its precise mechanisms are still being investigated, SIK1's role in these pathways makes it a potential drug target.
SIK1 is an emerging oncology target, though no genetic evidence currently links it to specific diseases. The existence of an approved drug suggests that modulating SIK1 activity can have therapeutic benefits in cancer.
SIK1 is currently targeted by one FDA-approved small molecule drug, TAFINLAR (Novartis), which has 4 indications in oncology. This single drug represents the entire current therapeutic landscape for SIK1.
Top SIK1 Drugs
Novartis is the only company with an approved drug targeting SIK1.
The lack of competition presents an opportunity for other companies to enter the SIK1 therapeutic space.
SIK1 Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets SIK1, using small molecule modality.
Exploring alternative modalities like antibodies or PROTACs could provide a competitive advantage and expand therapeutic options.
SIK1 Clinical Trials 93 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on SIK1. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 33 | 12 | 13 | 6 | 48% |
| Phase 2 | 49 | 15 | 12 | 22 | 56% |
| Phase 3 | 8 | 4 | 1 | 3 | 80% |
| Phase 4 | 3 | 0 | 0 | 3 | - |
Top Sponsors
By Modality
Top Conditions
Top Drugs
SIK1 Drug Approval Timeline (2013 - 2013)
The first and only drug targeting SIK1, TAFINLAR, was approved in 2013.
The absence of recent approvals suggests a potential saturation or a need for novel approaches to target SIK1.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 47 (7 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on SIK1. A trial counts if an approved drug acting on SIK1 is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.